Search Results

Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported first quarter 2024 financial results.

Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported fourth quarter and full year 2023 financial results.

Harvard Apparatus Regenerative Technology, Inc. announced that it officially executed a sponsored research agreement with Drs. Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.

Harvard Apparatus Regenerative Technology, Inc. announced that it will release Q3 2023 financial results on November 13, 2023 and host a conference call and webcast on the same day November 13, 2023 at 9:00 AM ET to discuss financial results and business updates for the third-quarter 2023.

Biostage, Inc. (OTCQB: formerly BSTG) announced today it has changed its corporate name back to Harvard Apparatus Regenerative Technology, Inc. and trade under the OTCQB symbol “HRGN” effective July 20, 2023.

Harvard Apparatus Regenerative Technology, Inc. today announced the Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency (EMA).